creatine has been researched along with Diabetes Mellitus, Type 2 in 67 studies
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-two type 2 DM patients with microalbuminuria were treated with 50-100 mg/day of Losartan for 6 months." | 9.12 | Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria. ( Berard, L; Hak, D; Khan, S; Ma, GM; Ni, LS; Penner, B; Shen, GX; Woo, V; Zhu, F, 2006) |
| "Twenty-two type 2 DM patients with microalbuminuria were treated with 50-100 mg/day of Losartan for 6 months." | 5.12 | Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria. ( Berard, L; Hak, D; Khan, S; Ma, GM; Ni, LS; Penner, B; Shen, GX; Woo, V; Zhu, F, 2006) |
| "The model highlighted a relevant contribution of inflammation (glycosylation pattern and HDL) and muscle (creatinine and creatine) in the development of type 2 diabetes as independent factors of hyperglycemia." | 4.31 | NMR-based metabolomic profiling identifies inflammation and muscle-related metabolites as predictors of incident type 2 diabetes mellitus beyond glucose: The Di@bet.es study. ( Amigó, N; Guardiola, M; Masana, L; Ozcariz, E; Rehues, P; Ribalta, J; Rojo-Martínez, G; Valdés, S, 2023) |
| "Patients with chronic kidney disease and type 2 diabetes have a higher risk of developing pneumonia as well as an increased risk of severe COVID-19-associated adverse events and mortality." | 3.11 | Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis. ( Agarwal, R; Ahlers, C; Anker, SD; Brinker, M; Filippatos, GS; Joseph, A; Lambelet, M; Lawatscheck, R; Pitt, B; Rossing, P; Ruilope, LM, 2022) |
| "Treatments of diabetic nephropathy (DN) delay the onset of end-stage renal disease." | 2.73 | Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. ( Bolton, WK; Degenhardt, TP; Khalifah, RG; McGill, JB; Schotzinger, RJ; Williams, ME, 2007) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | 2.70 | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001) |
| " Inhibiting SSAO activity by natural agents might reduce the potential adverse effects of creatine metabolism in population of T2DM." | 2.66 | Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus. ( Deng, Y; Papukashvili, D; Rcheulishvili, N, 2020) |
| "In patients with type 2 diabetes, BP variability contributes to the formation of CI through a pro-inflammatory mechanism (osteopontin), leading to impaired brain vascularization in general, white matter structure, and hippocampal metabolism." | 1.72 | [Blood pressure variability and neuroplasticity in patients with type 2 diabetes mellitus]. ( Kudlay, DA; Matveeva, MV; Samoilova, YG, 2022) |
| "The study outcome was incident type 2 diabetes, defined as a fasting plasma glucose ≥7." | 1.62 | Plasma creatine and incident type 2 diabetes in a general population-based cohort: The PREVEND study. ( Bakker, SJL; Connelly, MA; de Boer, RA; Douwes, RM; Dullaart, RPF; Flores-Guerrero, JL; Franssen, CFM; Garcia, E; Groothof, D; Kema, IP; Post, A; Schutten, JC; Swarte, JC; Wallimann, T, 2021) |
| "This study included 119 patients with type 2 diabetes mellitus (T2DM) and 76 non-diabetic subjects matched by sex and age." | 1.51 | Shortened mean erythrocyte age in female patients with type 2 diabetes mellitus. ( Ijima, H; Inada, S; Iwasaka, T; Jinnouchi, H; Koga, M; Okumiya, T; Ono, Y, 2019) |
| "Eighty six patients with Type 2 diabetes mellitus (T2DM) were enrolled for this study." | 1.43 | [Correlation between cognitive impairment and diabetic nephropathy in patients with Type 2 diabetes mellitus]. ( Niu, H; Shen, J; Shi, X; Wang, R; Wang, S; Wu, J; Yang, H; Zhang, Y; Zhou, S, 2016) |
| "Diabetic retinopathy was assessed by fundus photography and graded using modified Airlie House classification." | 1.38 | Systemic soluble tumor necrosis factor receptors 1 and 2 are associated with severity of diabetic retinopathy in Hispanics. ( Chen, YD; Cui, J; Guo, X; Ipp, E; Klein, BE; Klein, R; Kuo, JZ; Rotter, JI, 2012) |
| "Documented diabetic nephropathy prevalence showed marked variation across practices (range 0-100%) and was significantly negatively correlated with diabetes list size, albumin creatinine ratio testing rates and renin-angiotensin-aldosterone system blockade use and positively correlated with exception reporting rates." | 1.36 | Identifying additional patients with diabetic nephropathy using the UK primary care initiative. ( Cardwell, CR; Fogarty, DG; Hunter, SJ; Kee, F; Magee, GM; Murphy, MC; Savage, G, 2010) |
| "Patients with type 2 diabetes and major depression (n=20) were scanned along with patients with diabetes alone (n=24) and healthy controls (n=21) on a 1." | 1.34 | Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. ( Ajilore, O; Binesh, N; Darwin, C; Haroon, E; Kumar, A; Kumaran, S; Miller, J; Mintz, J; Thomas, MA, 2007) |
| "However, diabetic patients with ESRD secondary to dNP were significantly younger than those with vNP." | 1.33 | Rate of decline of GFR and progression of vascular disease in type 2 diabetic patients with diabetic or vascular nephropathy during the last three years before starting dialysis therapy. ( Biesenbach, G; Janko, O; Pieringer, H; Schmekal, B, 2006) |
| "Forty-seven patients with one decade of type 2 diabetes and 51 non-diabetic control subjects were studied." | 1.30 | Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes. ( Harmoinen, AP; Kouri, TT; Lehtimäki, TJ; Pasternack, AI; Rantalaiho, V; Turjanmaa, VM; Wirta, OR, 1999) |
| "He had no disorders that could induce microangiopathic hemolytic anemia other than diabetic microangiopathy." | 1.29 | Case report: diabetic microangiopathic hemolytic anemia and thrombocytopenia with antiphospholipid syndrome. ( Daidoh, H; Ishizuka, T; Morita, H; Suwa, T; Takeda, N; Yasuda, K, 1996) |
| "The high prevalence of small LDL in diabetic nephropathy was also observed even when hypertriglyceridemic or hypertensive subjects were excluded from each group." | 1.29 | High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. ( Adachi, M; Ebara, T; Hirano, T; Kurokawa, M; Nagano, S; Naito, H; Yoshino, G, 1996) |
| " In the healthy individuals, urinary guanidinoacetic acid excretion increased 5-fold by 2 h after dosing (15." | 1.28 | Clinical test of renal guanidinoacetic acid metabolism by oral citrulline and creatine loading. ( Kadono, K; Tetsutani, T; Yamaguchi, T; Yasunaga, K, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.99) | 18.7374 |
| 1990's | 6 (8.96) | 18.2507 |
| 2000's | 18 (26.87) | 29.6817 |
| 2010's | 29 (43.28) | 24.3611 |
| 2020's | 12 (17.91) | 2.80 |
| Authors | Studies |
|---|---|
| Mancini de Sousa, M | 1 |
| Nakata, MTK | 1 |
| Baldini, CES | 1 |
| de Oliveira-Sales, EB | 1 |
| Boim, MA | 1 |
| Martimbianco, ALC | 1 |
| Maquigussa, E | 1 |
| Matveeva, MV | 2 |
| Samoilova, YG | 2 |
| Kudlay, DA | 2 |
| Ijima, H | 2 |
| Hiratani, K | 1 |
| Jinnnouchi, H | 1 |
| Ono, Y | 2 |
| Kameyama, M | 1 |
| Okumiya, T | 2 |
| Koga, M | 2 |
| Jang, SY | 1 |
| Jung, Y | 1 |
| Lee, DH | 1 |
| Hwang, GS | 1 |
| Pitt, B | 1 |
| Agarwal, R | 1 |
| Anker, SD | 1 |
| Ruilope, LM | 1 |
| Rossing, P | 1 |
| Ahlers, C | 1 |
| Brinker, M | 1 |
| Joseph, A | 1 |
| Lambelet, M | 1 |
| Lawatscheck, R | 1 |
| Filippatos, GS | 1 |
| Ozcariz, E | 1 |
| Guardiola, M | 1 |
| Amigó, N | 1 |
| Rojo-Martínez, G | 1 |
| Valdés, S | 1 |
| Rehues, P | 1 |
| Masana, L | 1 |
| Ribalta, J | 1 |
| Ding, K | 1 |
| Li, Z | 1 |
| Lu, Y | 1 |
| Sun, L | 2 |
| Papukashvili, D | 1 |
| Rcheulishvili, N | 1 |
| Deng, Y | 1 |
| Post, A | 1 |
| Groothof, D | 1 |
| Schutten, JC | 1 |
| Flores-Guerrero, JL | 1 |
| Swarte, JC | 1 |
| Douwes, RM | 1 |
| Kema, IP | 1 |
| de Boer, RA | 1 |
| Garcia, E | 1 |
| Connelly, MA | 1 |
| Wallimann, T | 1 |
| Dullaart, RPF | 1 |
| Franssen, CFM | 1 |
| Bakker, SJL | 1 |
| Morita, S | 1 |
| Inai, Y | 1 |
| Minakata, S | 1 |
| Kishimoto, S | 1 |
| Manabe, S | 1 |
| Iwahashi, N | 1 |
| Ino, K | 1 |
| Ito, Y | 1 |
| Akamizu, T | 1 |
| Ihara, Y | 1 |
| Solis, MY | 1 |
| Artioli, GG | 3 |
| Gualano, B | 5 |
| Wu, GY | 1 |
| Zhang, Q | 1 |
| Wu, JL | 1 |
| Jing, L | 1 |
| Tan, Y | 1 |
| Qiu, TC | 1 |
| Zhao, J | 1 |
| Gazdzinski, SP | 1 |
| Gaździńska, AP | 1 |
| Orzeł, J | 1 |
| Redlisz-Redlicki, G | 1 |
| Pietruszka, M | 1 |
| Mojkowska, A | 1 |
| Pacho, RA | 1 |
| Wylezol, M | 1 |
| Inada, S | 1 |
| Jinnouchi, H | 1 |
| Iwasaka, T | 1 |
| Zhou, Y | 1 |
| Qi, C | 1 |
| Li, S | 1 |
| Shao, X | 1 |
| Mou, S | 1 |
| Ni, Z | 1 |
| Medrano Navarro, AL | 1 |
| Justel Enríquez, A | 1 |
| Alameda Serrano, J | 1 |
| Blasco Lamarca, Y | 1 |
| Sáenz Abad, D | 1 |
| Gimeno Orna, JA | 1 |
| Fried, PJ | 1 |
| Pascual-Leone, A | 1 |
| Bolo, NR | 1 |
| Lin, Y | 1 |
| Zhou, J | 1 |
| Sha, L | 1 |
| Li, Y | 1 |
| Qu, X | 1 |
| Liu, L | 1 |
| Chen, H | 1 |
| An, Z | 1 |
| Wang, Y | 2 |
| Sun, C | 1 |
| Zhang, M | 1 |
| Sun, X | 1 |
| Zhang, Z | 2 |
| Meng, Q | 1 |
| Chen, J | 1 |
| Ma, X | 1 |
| Geng, H | 1 |
| Ohkuma, T | 1 |
| Fujii, H | 1 |
| Iwase, M | 1 |
| Ogata-Kaizu, S | 1 |
| Ide, H | 1 |
| Kikuchi, Y | 1 |
| Idewaki, Y | 1 |
| Jodai, T | 1 |
| Hirakawa, Y | 1 |
| Nakamura, U | 1 |
| Kitazono, T | 1 |
| Hajek, T | 1 |
| Calkin, C | 1 |
| Blagdon, R | 1 |
| Slaney, C | 1 |
| Alda, M | 1 |
| Ma, Y | 1 |
| Huang, D | 1 |
| Zhang, R | 1 |
| Xu, S | 1 |
| Feng, S | 1 |
| Zhao, C | 1 |
| Luo, Q | 1 |
| He, F | 1 |
| Peng, F | 1 |
| Xia, X | 1 |
| Huang, F | 1 |
| Yu, X | 1 |
| Furuyama, JK | 1 |
| Nagarajan, R | 1 |
| Roberts, CK | 1 |
| Lee, CC | 1 |
| Hahn, TJ | 1 |
| Thomas, MA | 2 |
| Rodriguez-Poncelas, A | 1 |
| Miravet-Jiménez, S | 1 |
| Casellas, A | 1 |
| Barrot-De La Puente, JF | 1 |
| Franch-Nadal, J | 1 |
| López-Simarro, F | 1 |
| Mata-Cases, M | 1 |
| Mundet-Tudurí, X | 1 |
| Shi, X | 1 |
| Zhang, Y | 1 |
| Niu, H | 1 |
| Wang, R | 1 |
| Shen, J | 1 |
| Zhou, S | 1 |
| Yang, H | 1 |
| Wang, S | 1 |
| Wu, J | 1 |
| Achilles, EI | 1 |
| Maus, V | 1 |
| Fink, GR | 1 |
| Maintz, D | 1 |
| van Eimeren, T | 1 |
| Mpotsaris, A | 1 |
| Pinto, CL | 1 |
| Botelho, PB | 1 |
| Pimentel, GD | 1 |
| Campos-Ferraz, PL | 1 |
| Mota, JF | 1 |
| Simsek, IB | 1 |
| Artunay, O | 1 |
| Heikkilä, O | 1 |
| Lundbom, N | 1 |
| Timonen, M | 1 |
| Groop, PH | 1 |
| Heikkinen, S | 1 |
| Mäkimattila, S | 1 |
| Tiehuis, A | 1 |
| van der Meer, F | 1 |
| Mali, W | 1 |
| Pleizier, M | 1 |
| Biessels, GJ | 1 |
| Kappelle, J | 1 |
| Luijten, P | 1 |
| Rocic, B | 2 |
| Bajuk, NB | 1 |
| Rocic, P | 2 |
| Weber, DS | 1 |
| Boras, J | 1 |
| Lovrencic, MV | 1 |
| Elley, CR | 1 |
| Robinson, E | 1 |
| Kenealy, T | 1 |
| Bramley, D | 1 |
| Drury, PL | 1 |
| Xia, JF | 1 |
| Hu, P | 1 |
| Liang, QL | 1 |
| Zou, TT | 1 |
| Wang, YM | 1 |
| Luo, GA | 1 |
| DE Salles Painneli, V | 1 |
| Roschel, H | 3 |
| Neves, M | 1 |
| De Sá Pinto, AL | 1 |
| Da Silva, ME | 2 |
| Cunha, MR | 2 |
| Otaduy, MC | 3 |
| Leite, Cda C | 2 |
| Ferreira, JC | 2 |
| Pereira, RM | 1 |
| Brum, PC | 1 |
| Bonfá, E | 2 |
| Lancha, AH | 3 |
| de Salles Painelli, V | 2 |
| Lugaresi, R | 2 |
| Dorea, E | 1 |
| Lima, FR | 1 |
| Seguro, AC | 1 |
| Shimizu, MH | 1 |
| Sapienza, MT | 1 |
| da Costa Leite, C | 1 |
| Lancha Junior, AH | 1 |
| Zhao, LC | 1 |
| Zhang, XD | 1 |
| Liao, SX | 1 |
| Gao, HC | 1 |
| Wang, HY | 1 |
| Lin, DH | 1 |
| Magee, GM | 1 |
| Hunter, SJ | 1 |
| Cardwell, CR | 1 |
| Savage, G | 1 |
| Kee, F | 1 |
| Murphy, MC | 1 |
| Fogarty, DG | 1 |
| Znaor, A | 1 |
| Weber, D | 1 |
| Vučić Lovrenčić, M | 1 |
| Painelli de Salles, V | 1 |
| Queiroz, AC | 1 |
| Artioli, G | 1 |
| Kuo, JZ | 1 |
| Guo, X | 1 |
| Klein, R | 1 |
| Klein, BE | 1 |
| Cui, J | 1 |
| Rotter, JI | 1 |
| Ipp, E | 1 |
| Chen, YD | 1 |
| Alves, CR | 1 |
| de Siqueira-Filho, MA | 1 |
| Carvalho, CR | 1 |
| Goto, A | 1 |
| Marre, M | 1 |
| Garcia Puig, J | 1 |
| Kokot, F | 1 |
| Fernandez, M | 1 |
| Jermendy, G | 1 |
| Opie, L | 1 |
| Moyseev, V | 1 |
| Scheen, A | 1 |
| Ionescu-Tirgoviste, C | 1 |
| Saldanha, MH | 1 |
| Halabe, A | 1 |
| Williams, B | 1 |
| Mion, D | 1 |
| Ruiz, M | 1 |
| Hermansen, K | 1 |
| Tuomilehto, J | 1 |
| Finizola, B | 1 |
| Pozza, G | 1 |
| Chastang, C | 1 |
| Ollivier, JP | 1 |
| Amouyel, P | 1 |
| Asmar, R | 1 |
| Rosenbaum, P | 1 |
| Gimeno, SG | 1 |
| Sanudo, A | 1 |
| Franco, LJ | 1 |
| Ferreira, SR | 1 |
| Wihler, C | 1 |
| Schäfer, S | 1 |
| Schmid, K | 1 |
| Deemer, EK | 1 |
| Münch, G | 1 |
| Bleich, M | 1 |
| Busch, AE | 1 |
| Dingermann, T | 1 |
| Somoza, V | 1 |
| Baynes, JW | 1 |
| Huber, J | 1 |
| Tseng, CH | 1 |
| Tseng, CP | 1 |
| Tai, TY | 1 |
| Chong, CK | 1 |
| Op't Eijnde, B | 1 |
| Jijakli, H | 1 |
| Hespel, P | 1 |
| Malaisse, WJ | 1 |
| Biesenbach, G | 1 |
| Schmekal, B | 1 |
| Pieringer, H | 1 |
| Janko, O | 1 |
| Ajilore, O | 1 |
| Haroon, E | 1 |
| Kumaran, S | 1 |
| Darwin, C | 1 |
| Binesh, N | 1 |
| Mintz, J | 1 |
| Miller, J | 1 |
| Kumar, A | 1 |
| Kim, CS | 1 |
| Sohn, EJ | 1 |
| Kim, YS | 1 |
| Jung, DH | 1 |
| Jang, DS | 1 |
| Lee, YM | 1 |
| Kim, DH | 1 |
| Kim, JS | 1 |
| Woo, V | 1 |
| Ni, LS | 1 |
| Hak, D | 1 |
| Berard, L | 1 |
| Zhu, F | 1 |
| Khan, S | 1 |
| Ma, GM | 1 |
| Penner, B | 1 |
| Shen, GX | 1 |
| Williams, ME | 1 |
| Bolton, WK | 1 |
| Khalifah, RG | 1 |
| Degenhardt, TP | 1 |
| Schotzinger, RJ | 1 |
| McGill, JB | 1 |
| Wang, H | 1 |
| Meng, QH | 1 |
| Gordon, JR | 1 |
| Khandwala, H | 1 |
| Wu, L | 1 |
| Srivastava, PM | 1 |
| Calafiore, P | 1 |
| Macisaac, RJ | 1 |
| Patel, SK | 1 |
| Thomas, MC | 1 |
| Jerums, G | 1 |
| Burrell, LM | 1 |
| Modi, S | 1 |
| Bhattacharya, M | 1 |
| Sekhri, T | 1 |
| Rana, P | 1 |
| Tripathi, RP | 1 |
| Khushu, S | 1 |
| Morita, H | 1 |
| Suwa, T | 1 |
| Daidoh, H | 1 |
| Takeda, N | 1 |
| Ishizuka, T | 1 |
| Yasuda, K | 1 |
| Perfetto, F | 1 |
| Tarquini, R | 1 |
| de Leonardis, V | 1 |
| Piluso, A | 1 |
| Lombardi, V | 1 |
| Tarquini, B | 1 |
| Hirano, T | 1 |
| Naito, H | 1 |
| Kurokawa, M | 1 |
| Ebara, T | 1 |
| Nagano, S | 1 |
| Adachi, M | 1 |
| Yoshino, G | 1 |
| Harmoinen, AP | 1 |
| Kouri, TT | 1 |
| Wirta, OR | 1 |
| Lehtimäki, TJ | 1 |
| Rantalaiho, V | 1 |
| Turjanmaa, VM | 1 |
| Pasternack, AI | 1 |
| Brenner, BM | 1 |
| Cooper, ME | 1 |
| de Zeeuw, D | 1 |
| Keane, WF | 1 |
| Mitch, WE | 1 |
| Parving, HH | 1 |
| Remuzzi, G | 1 |
| Snapinn, SM | 1 |
| Shahinfar, S | 1 |
| Zywiec, J | 1 |
| Grzeszczak, W | 1 |
| Pierzchała, K | 1 |
| Kadono, K | 1 |
| Yamaguchi, T | 1 |
| Tetsutani, T | 1 |
| Yasunaga, K | 1 |
| Matsumoto, E | 1 |
| Matsumoto, G | 1 |
| Ooshima, A | 1 |
| Kikuoka, H | 1 |
| Bessho, H | 1 |
| Miyamura, K | 1 |
| Nanjo, K | 1 |
| Dullaart, RP | 1 |
| Roelse, H | 1 |
| Sluiter, WJ | 1 |
| Doorenbos, H | 1 |
| Spesivtseva, VG | 1 |
| Mamaeva, GG | 1 |
| Starosel'tseva, LK | 1 |
| Kozlova, EG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Dia[NCT02540993] | Phase 3 | 5,734 participants (Actual) | Interventional | 2015-09-17 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus a[NCT02545049] | Phase 3 | 7,352 participants (Actual) | Interventional | 2015-09-17 | Completed | ||
| Efficacy and Safety of Creatine Supplementation Combined With Exercise Training in Type 2 Diabetic Patients[NCT00992043] | 28 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)[NCT05037695] | Phase 4 | 40 participants (Anticipated) | Interventional | 2021-07-21 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to the first occurrence of a hospitalization event were evaluated. Number of participants with the event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 1263 |
| Placebo | 1321 |
Count of participants and time from randomization until death due to any cause were evaluated. Number of participants with outcome death is reported as descriptive result and hazard ratio is reported as statistical analysis. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table. (NCT02540993)
Timeframe: From randomization up until death due to any cause, or censoring at the end of the study visit, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 219 |
| Placebo | 244 |
First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change. (NCT02540993)
Timeframe: From baseline up until Month 4
| Intervention | Ratio (Least Squares Mean) |
|---|---|
| Finerenone | 0.655 |
| Placebo | 0.952 |
Count of participants and time from randomization to the first occurrence of the key secondary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the key secondary CV composite endpoint, or censoring at the end of the study, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 367 |
| Placebo | 420 |
Count of participants and time from randomization to the first occurrence of the secondary renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the composite primary endpoint, or censoring at the end of the study, with an average of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 252 |
| Placebo | 326 |
Count of participants and time from randomization to the first occurrence of the primary renal composite outcome, onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were evaluated. Number of participants with the outcome event is reported as descriptive result and hazard ratio is reported as statistical analysis. (NCT02540993)
Timeframe: From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 504 |
| Placebo | 600 |
Number of participants with first occurrence of a hospitalization event were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average study duration of 41 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 1573 |
| Placebo | 1605 |
Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table. (NCT02545049)
Timeframe: From randomization up until death due to any cause, or censoring at the end of the study, with an average study duration of 41 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 333 |
| Placebo | 370 |
First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change. (NCT02545049)
Timeframe: From baseline up until Month 4
| Intervention | Ratio (Least Squares Mean) |
|---|---|
| Finerenone | 0.624 |
| Placebo | 0.922 |
Number of participants with the first occurrence of the primary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 458 |
| Placebo | 519 |
Number of participants with first occurrence of the renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 108 |
| Placebo | 139 |
Number of participants with first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were reported as descriptive result. (NCT02545049)
Timeframe: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Finerenone | 350 |
| Placebo | 395 |
5 reviews available for creatine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Creatine Supplementation in Type 2 Diabetic Patients: A Systematic Review of Randomized Clinical Trials.
Topics: Blood Glucose; Creatine; Diabetes Mellitus, Type 2; Dietary Supplements; Glyburide; Humans; Hypoglyc | 2022 |
Beneficial Impact of Semicarbazide-Sensitive Amine Oxidase Inhibition on the Potential Cytotoxicity of Creatine Supplementation in Type 2 Diabetes Mellitus.
Topics: Adipokines; Amine Oxidase (Copper-Containing); Caffeine; Copper; Creatine; Diabetes Mellitus, Type 2 | 2020 |
Potential of Creatine in Glucose Management and Diabetes.
Topics: Animals; Creatine; Diabetes Mellitus, Type 2; Dietary Supplements; Exercise; Glucose; Glucose Transp | 2021 |
Changes in cerebral metabolites in type 2 diabetes mellitus: A meta-analysis of proton magnetic resonance spectroscopy.
Topics: Aspartic Acid; Brain; Case-Control Studies; Choline; Creatine; Diabetes Mellitus, Type 2; Humans; In | 2017 |
Creatine supplementation and glycemic control: a systematic review.
Topics: Animals; Carbohydrate Metabolism; Creatine; Diabetes Mellitus, Type 2; Dietary Supplements; Glucose; | 2016 |
12 trials available for creatine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
Topics: Albumins; Anti-Inflammatory Agents; COVID-19; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropa | 2022 |
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
Topics: Albumins; Anti-Inflammatory Agents; COVID-19; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropa | 2022 |
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
Topics: Albumins; Anti-Inflammatory Agents; COVID-19; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropa | 2022 |
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
Topics: Albumins; Anti-Inflammatory Agents; COVID-19; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropa | 2022 |
Diabetic Nephropathy Can Be Treated with Calcium Dobesilate by Alleviating the Chronic Inflammatory State and Improving Endothelial Cell Function.
Topics: Aged; Albuminuria; Anti-Inflammatory Agents; Calcium Dobesilate; Chronic Disease; Creatine; Cross-Se | 2018 |
Comparison of antihyperglycemic effects of creatine and metformin in type II diabetic patients.
Topics: Blood Glucose; Creatine; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic | 2009 |
Creatine in type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Topics: Blood Glucose; Blotting, Western; Creatine; Diabetes Mellitus, Type 2; Dietary Supplements; Double-B | 2011 |
Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial.
Topics: Creatine; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Method; Female; Humans; Kidne | 2011 |
Comparison of antihyperglycemic effects of creatine and glibenclamide in type II diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Creatine; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gl | 2011 |
Creatine supplementation does not augment muscle carnosine content in type 2 diabetic patients.
Topics: Body Mass Index; Creatine; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Method; Exer | 2011 |
Creatine-induced glucose uptake in type 2 diabetes: a role for AMPK-α?
Topics: AMP-Activated Protein Kinases; Antigens, CD; Biopsy; Creatine; Diabetes Mellitus, Type 2; Double-Bli | 2012 |
Effect of indapamide SR on microalbuminuria--the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia)--rationale and protocol for the main trial.
Topics: Adult; Aged; Albuminuria; Clinical Protocols; Creatine; Delayed-Action Preparations; Diabetes Mellit | 2003 |
Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Coagulation Factors; Blood | 2006 |
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.
Topics: Adolescent; Adult; Aged; Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ne | 2007 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
50 other studies available for creatine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
[Blood pressure variability and neuroplasticity in patients with type 2 diabetes mellitus].
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Choline; Creatine; Diabetes Mellitus, Type 2; | 2022 |
[Blood pressure variability and brain neuroimaging in patients with type 2 diabetes].
Topics: Blood Pressure; Brain; Brain Diseases; Choline; Creatine; Diabetes Mellitus, Type 2; Humans; Neuroim | 2022 |
Measurement of erythrocyte creatine might be useful for diagnosing latent hemolysis.
Topics: Anemia, Hemolytic; Blood Glucose; Creatine; Diabetes Mellitus, Type 2; Erythrocytes; Glycated Hemogl | 2022 |
NMR-based metabolomic analysis of human plasma to examine the effect of exposure to persistent organic pollutants.
Topics: Cholesterol; Creatine; Creatinine; Diabetes Mellitus, Type 2; Environmental Pollutants; Formates; Hu | 2022 |
NMR-based metabolomic profiling identifies inflammation and muscle-related metabolites as predictors of incident type 2 diabetes mellitus beyond glucose: The Di@bet.es study.
Topics: Creatine; Creatinine; Diabetes Mellitus, Type 2; Glucose; Humans; Inflammation; Magnetic Resonance S | 2023 |
Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Topics: Bayes Theorem; Cardiovascular Diseases; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2023 |
Plasma creatine and incident type 2 diabetes in a general population-based cohort: The PREVEND study.
Topics: Blood Glucose; Creatine; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Middle | 2021 |
Quantification of serum C-mannosyl tryptophan by novel assay to evaluate renal function and vascular complications in patients with type 2 diabetes.
Topics: Biomarkers; Chromatography, Liquid; Creatine; Cystatin C; Diabetes Mellitus, Type 2; Diabetic Angiop | 2021 |
Intragastric balloon therapy leads to normalization of brain magnetic resonance spectroscopic markers of diabetes in morbidly obese patients.
Topics: Adipose Tissue; Body Mass Index; Body Weight; Brain; Creatine; Diabetes Mellitus, Type 2; Female; Ga | 2018 |
Shortened mean erythrocyte age in female patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Case-Control Studies; Creatine; Diabetes Mellitus, Type 2; Erythrocytes; Female | 2019 |
Total and cardiovascular mortality risk according to KDIGO guidelines classification in type 2 diabetic patients.
Topics: Adult; Albuminuria; Analysis of Variance; Cardiovascular Diseases; Cause of Death; Chi-Square Distri | 2019 |
Diabetes and the link between neuroplasticity and glutamate in the aging human motor cortex.
Topics: Aged; Aged, 80 and over; Aging; Aspartic Acid; Creatine; Diabetes Mellitus, Type 2; Female; Glucose; | 2019 |
Metabolite differences in the lenticular nucleus in type 2 diabetes mellitus shown by proton MR spectroscopy.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Biomarkers; Choline; Corpus Striatum; Creatine; Diabetes Mel | 2013 |
Brain metabolite changes in patients with type 2 diabetes and cerebral infarction using proton magnetic resonance spectroscopy.
Topics: Aged; Aspartic Acid; Blood Glucose; Brain; Cerebral Infarction; Choline; Creatine; Diabetes Mellitus | 2014 |
Association between sleep duration and urinary albumin excretion in patients with type 2 diabetes: the Fukuoka diabetes registry.
Topics: Aged; Albuminuria; Creatine; Diabetes Mellitus, Type 2; Female; Humans; Japan; Male; Middle Aged; Re | 2013 |
Type 2 diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain; Creatine; Cross-Sectional Studies; Diabetes Mellitus, | 2015 |
[Simultaneous determination of four common nonprotein nitrogen substances in urine by high performance liquid chromatography].
Topics: Chromatography, High Pressure Liquid; Creatine; Creatinine; Diabetes Mellitus, Type 2; Humans; Limit | 2013 |
Establishing HbA1c -mean blood glucose formulae for patients on continuous ambulatory peritoneal dialysis.
Topics: Adult; Blood Glucose; Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephr | 2014 |
A pilot validation of multi-echo based echo-planar correlated spectroscopic imaging in human calf muscles.
Topics: Adult; Bone Marrow; Choline; Creatine; Diabetes Mellitus, Type 2; Echo-Planar Imaging; Extracellular | 2014 |
Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain).
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Creatine; Cross-Sectional Studies; Diabetes Mellitus, | 2015 |
[Correlation between cognitive impairment and diabetic nephropathy in patients with Type 2 diabetes mellitus].
Topics: Adult; Aspartic Acid; Case-Control Studies; Cerebrum; Choline; Cognition; Cognition Disorders; Creat | 2016 |
[Hemichorea with Contralateral High Signal Intensity Putaminal Lesion on T1-Weighted Images in Non-Ketotic Hyperglycemia].
Topics: Aspartic Acid; Choline; Chorea; Creatine; Diabetes Complications; Diabetes Mellitus, Type 2; Diffusi | 2016 |
Evaluation of Biochemical Composition of Vitreous of Eyes of Diabetic Patients Using Proton Magnetic Resonance Spectroscopy.
Topics: Adult; Biomarkers; Creatine; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fluorescein An | 2017 |
Risk for metabolic syndrome predisposes to alterations in the thalamic metabolism.
Topics: Adult; Anthropometry; Aspartic Acid; Blood Glucose; Choline; Creatine; Diabetes Mellitus, Type 2; Hu | 2008 |
MR spectroscopy of cerebral white matter in type 2 diabetes; no association with clinical variables and cognitive performance.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognition; Cognition Disorders; Creatine; Di | 2010 |
Derivation and validation of a new cardiovascular risk score for people with type 2 diabetes: the new zealand diabetes cohort study.
Topics: Albuminuria; Cardiovascular Diseases; Cohort Studies; Creatine; Diabetes Mellitus, Type 2; Female; G | 2010 |
Correlations of creatine and six related pyrimidine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients.
Topics: Aged; Chromatography, High Pressure Liquid; Creatine; Cytidine; Cytosine; Deoxyuridine; Diabetes Mel | 2010 |
A metabonomic comparison of urinary changes in Zucker and GK rats.
Topics: Acids, Acyclic; Animals; Biomarkers; Creatine; Diabetes Mellitus, Type 2; Dimethylamines; Disease Mo | 2010 |
Identifying additional patients with diabetic nephropathy using the UK primary care initiative.
Topics: Creatine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progre | 2010 |
Systemic soluble tumor necrosis factor receptors 1 and 2 are associated with severity of diabetic retinopathy in Hispanics.
Topics: Blood Pressure; Cohort Studies; Creatine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabet | 2012 |
Diabetic nephropathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2002 |
Independent impact of glycemia and blood pressure in albuminuria on high-risk subjects for metabolic syndrome.
Topics: Aged; Albuminuria; Analysis of Variance; Brazil; Chi-Square Distribution; Creatine; Diabetes Mellitu | 2004 |
Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Ascorbic Acid; Blood Glucose; Chromatography, Hig | 2005 |
Effect of angiotensin blockade on the association between albuminuria and peripheral arterial disease in elderly Taiwanese patients with type 2 diabetes mellitus.
Topics: Aged; Albumins; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2005 |
Creatine supplementation increases soleus muscle creatine content and lowers the insulinogenic index in an animal model of inherited type 2 diabetes.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Body Weight; Creatine; Diabetes Mellitus, Type 2; Di | 2006 |
Rate of decline of GFR and progression of vascular disease in type 2 diabetic patients with diabetic or vascular nephropathy during the last three years before starting dialysis therapy.
Topics: Aged; Blood Pressure; Cholesterol; Creatine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabe | 2006 |
Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain Chemistry; Choline; Creatine; Depressive Disord | 2007 |
Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats.
Topics: Administration, Oral; Animals; Blood Glucose; Collagen Type IV; Creatine; Diabetes Mellitus, Experim | 2007 |
Proinflammatory and proapoptotic effects of methylglyoxal on neutrophils from patients with type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Anti-Inflammatory Agents; Apoptosis; Blood Glucose; Caspase 3; Creatine; Cytokine | 2007 |
Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes.
Topics: Aging; Analysis of Variance; Antihypertensive Agents; Cardiomegaly; Creatine; Cross-Sectional Studie | 2008 |
Assessment of the metabolic profile in Type 2 diabetes mellitus and hypothyroidism through proton MR spectroscopy.
Topics: Adult; Aspartic Acid; Brain; Choline; Creatine; Diabetes Mellitus, Type 2; Female; Humans; Hypothyro | 2008 |
Case report: diabetic microangiopathic hemolytic anemia and thrombocytopenia with antiphospholipid syndrome.
Topics: Adult; Anemia, Hemolytic; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Creatine; Diabete | 1996 |
Angiopathy affects circulating endothelin-1 levels in type 2 diabetic patients.
Topics: Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Creatine; Diabetes Mellitus | 1995 |
High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy.
Topics: Aged; Albuminuria; Apoproteins; Blood Glucose; Body Mass Index; Carrier Proteins; Cholesterol Ester | 1996 |
Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes.
Topics: Aged; Biomarkers; Creatine; Cystatin C; Cystatins; Diabetes Mellitus, Type 2; Evaluation Studies as | 1999 |
[Bone complication in diabetes subjects with good metabolic control and without longterm complications: certain problems. Part II. Basal parameters of bone turnover].
Topics: Alkaline Phosphatase; Bone Resorption; Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 2001 |
Clinical test of renal guanidinoacetic acid metabolism by oral citrulline and creatine loading.
Topics: 17-Ketosteroids; Amidinotransferases; Animals; Chronic Disease; Citrulline; Creatine; Diabetes Melli | 1992 |
Serum type IV collagen concentrations in diabetic patients with microangiopathy as determined by enzyme immunoassay with monoclonal antibodies.
Topics: Aged; Antibodies, Monoclonal; Beta-Globulins; Blood Urea Nitrogen; Collagen; Creatine; Diabetes Mell | 1990 |
Variability of albumin excretion in diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Creatine; Data Collection; Diabetes Mellitu | 1989 |
[Early detection of nephroangiopathy in patients with diabetes mellitus and approaches to its correction].
Topics: Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neph | 1989 |